Adaptimmune Therapeutics Plc (ADAPY)
0.025
-0.01
(-21.88%)
USD |
OTCM |
Oct 22, 16:00
Adaptimmune Therapeutics Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 29.25M |
| October 21, 2026 | 31.10M |
| October 20, 2026 | 31.23M |
| October 19, 2026 | 31.90M |
| October 16, 2026 | 31.10M |
| October 15, 2026 | 31.45M |
| October 14, 2026 | 30.57M |
| October 13, 2026 | 30.17M |
| October 12, 2026 | 30.57M |
| October 09, 2026 | 30.57M |
| October 08, 2026 | 30.04M |
| October 07, 2026 | 30.01M |
| October 06, 2026 | 30.31M |
| October 05, 2026 | 30.57M |
| October 02, 2026 | 32.43M |
| October 01, 2026 | 32.69M |
| September 30, 2026 | 32.69M |
| September 29, 2026 | 29.51M |
| September 28, 2026 | 29.72M |
| September 25, 2026 | 29.38M |
| September 24, 2026 | 28.72M |
| September 23, 2026 | 29.51M |
| September 22, 2026 | 29.59M |
| September 21, 2026 | 29.67M |
| September 18, 2026 | 28.58M |
| Date | Value |
|---|---|
| September 17, 2026 | 28.72M |
| September 16, 2026 | 29.25M |
| September 15, 2026 | 29.25M |
| September 14, 2026 | 28.98M |
| September 11, 2026 | 28.62M |
| September 10, 2026 | 28.75M |
| September 09, 2026 | 29.25M |
| September 08, 2026 | 29.51M |
| September 04, 2026 | 29.72M |
| September 03, 2026 | 29.51M |
| September 02, 2026 | 29.25M |
| September 01, 2026 | 29.78M |
| August 31, 2026 | 28.58M |
| August 28, 2026 | 30.04M |
| August 27, 2026 | 30.28M |
| August 26, 2026 | 29.63M |
| August 25, 2026 | 29.25M |
| August 24, 2026 | 29.40M |
| August 21, 2026 | 29.78M |
| August 20, 2026 | 29.78M |
| August 19, 2026 | 29.78M |
| August 18, 2026 | 29.43M |
| August 17, 2026 | 30.31M |
| August 14, 2026 | 30.31M |
| August 13, 2026 | 29.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oxford Biomedica Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 5.783B |
| Autolus Therapeutics Plc | 585.22M |
| Bicycle Therapeutics Plc | -311.47M |
| Scancell Holdings Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.72M |
| Revenue (Quarterly) | 13.85M |
| Total Expenses (Quarterly) | 44.56M |
| EPS Diluted (Quarterly) | -0.1163 |